drugset
drugset / Trial / NCT04179084

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

NCT04179084 ↗

Phase 2 Unknown 30 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer

Timeline

Start
2019-08-28
Primary completion
2020-03-01
Completion
2020-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 5 mg —
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

colorectal cancer